This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abattis Engages British Columbia Institute Of Technology To Study Growth Rates And Compounds In Spinach

VANCOUVER, Feb. 4, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of BCIT to study the growth rates and novel compounds present in baby spinach.

Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to start on this project as it will substantiate the Vertical Automated Grow System (VAGS) acquired from Vertical Designs Ltd. and serve as a benchmark for growing, processing and the proprietary extraction of botanicals under strict Standard Operating Protocols to achieve pharmaceutical grade products."  Mr. Withrow went on to state, "This is our first step toward producing bio-pharma grade botanicals that are standardized to targeted phytochemicals."

Dr. Paula N. Brown, Director of Applied Research for BCIT's Natural Health & Food Products Research Group, stated, "The proposed research project focuses on the controlled and sustainable production of plants to meet the demand for a traceable and consistent supply of botanical materials for development of biopharmaceuticals."  Under the direction of Dr. Brown, BCIT has worked with the natural health product sector for over a decade conducting applied research, including product development, establishment of quality standards and regulatory compliance. By providing fundamental investigations on product quality, safety and efficacy, BCIT supports industry through the entire continuum, from grower to manufacturer, ensuring product integrity is maintained. "We are excited to be working with this group", continued Dr. Brown, "as the expertise and technology afforded by the combination of the VAGS and Abattis could serve as a model for development of value-added products and potential therapeutics from a wide variety of medicinal plants.

About Abattis Bioceuticals Corp. Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and bio-similar compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at

About BCIT


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs